To the contrary: it might prove quite meaningful...
The purpose behind the 60-day follow up is to determine/measure Brilacidin's efficacy against the so-called long-haul symptoms.
If there's a statistically discernible and beneficial distinction between the treatment and placebo group with regard to long-haul morbidity (presuming the treatment group shows a lower incidence of symptoms), it would be a significant data point.
I recognize that all of the outcomes in the trial protocol are measured through day 29, but if there's clear and irrefutable benefit conferred through day 60 amongst the treatment group it won't be ignored.